Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21580050 | 0.90 | HPGD (0.42) | PPARAHPGDPPARD | |
| SCHEMBL23686573 | 0.86 | PPARA (0.39) | PPARAPDE2AEGLN1HPGDPPARD | |
| SCHEMBL21580148 | 0.86 | KDM4E (0.43) | PPARAHDAC1PDE2AEGLN1HPGD | |
| SCHEMBL21580115 | 0.81 | SCN3A (0.50) | HDAC6HDAC1LMNA | |
| SCHEMBL21580095 | 0.81 | NAMPT (0.49) | PPARAHDAC1HPGDLMNASMN1; SMN2 | |
| SCHEMBL21580145 | 0.77 | PPARG (0.41) | PPARAHPGDPPARD | |
| SCHEMBL23691868 | 0.73 | HPGD (0.42) | HDAC6HDAC1HPGDLMNA | |
| SCHEMBL21580078 | 0.73 | LMNA (0.45) | HPGDLMNA | |
| SCHEMBL21580062 | 0.73 | NAMPT (0.47) | HDAC1LMNASMN1; SMN2 | |
| SCHEMBL21580106 | 0.69 | SCN3A (0.52) | HDAC1HPGDLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210230157-A1 | PAIN TREATING COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230157-A1 | PAIN TREATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, TRPV3 | PPARA 1044/4885HDAC6 315/4885HDAC1 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.